Skip to main content

PTA failures of AV graft lesions

Percutaneous transluminal angioplasty (PTA) has significant limitations when treating Arteriovenous (AV) access lesions1

  • Patency rates diminish with each successive angioplasty procedure1,2
    • In the REVISE Clinical Study, patients undergoing PTA who had a previous intervention at the target lesion had lower primary patency at 6 months when compared with patients with no prior interventions at the target lesion (29.2% vs 43.9%)1 
  • The 2006 KDOQI guidelines acknowledge that alternatives to PTA should be considered when PTA fails twice within three months3

The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface* has proven patency independent of the number of prior interventions1

Proven patency

  • Provided consistent patency independent of the number of times a lesion has previously been treated1 
Six month target lesion chart

Stent graft design provides unique benefits to the treatment of lesions refractory to PTA

  • ePTFE flow lumen covers and seals off diseased tissue

Connect with a Gore technical sales associate

* Heparin Bioactive Surface is synonymous with the CBAS Heparin Surface.

  1. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. Journal of Vascular Surgery 2016;64(5):1400-1410.e1.
  2. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995;195(1):135-139.
  3. Kidney Disease Outcomes, Quality Initiative (KDOQI). Clinical Practice Guidelines and Clinical Practice Recommendations. 2006 Updates. National Kidney Foundation Web site. . Accessed July 17, 2018.